

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr NEXVIAZYME™

avalglucosidase alfa for injection

Lyophilized Powder
100 mg/vial, intravenous infusion

Enzyme Replacement Therapy

sanofi-aventis Canada Inc.
1755 Steeles Avenue West
Toronto ON
M2R 3T4

Date of Initial Approval:
November 12, 2021

Date of revision:
May 11, 2023

s-a version 1.2 dated March
13, 2024

Submission Control No: 270061

RECENT MAJOR LABEL CHANGES

[Section number and heading], [Subsection number and heading]	[MM/YYYY]
[Section number and heading], [Subsection number and heading]	[MM/YYYY]

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	4
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment	5
4.3 Reconstitution.....	5
4.4 Administration.....	5
4.7 Instructions for Preparation and Use	6
5 OVERDOSAGE	7
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	8
7 WARNINGS AND PRECAUTIONS	8
7.1 Special Populations.....	11
7.1.1 Pregnant Women	11
7.1.2 Breast-feeding	11
7.1.3 Pediatrics.....	11
7.1.4 Geriatrics.....	11
8 ADVERSE REACTIONS	11
8.1 Adverse Reaction Overview	11
8.2 Clinical Trial Adverse Reactions.....	12
9 DRUG INTERACTIONS	14
9.4 Drug-Drug Interactions	14
9.5 Drug-Food Interactions.....	14
9.6 Drug-Herb Interactions	14
9.7 Drug-Laboratory Test Interactions.....	14
10 CLINICAL PHARMACOLOGY	14
10.1 Mechanism of Action	14
10.2 Pharmacodynamics	15

10.3	Pharmacokinetics	15
11	STORAGE, STABILITY AND DISPOSAL	16
	PART II: SCIENTIFIC INFORMATION.....	17
13	PHARMACEUTICAL INFORMATION	17
14	CLINICAL TRIALS.....	18
14.1	Trial Design and Study Demographics	18
14.2	Study Results.....	18
14.4	Immunogenicity.....	19
16	NON-CLINICAL TOXICOLOGY	21
	PATIENT MEDICATION INFORMATION.....	23

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Nexviazyme™ (avalglucosidase alfa for injection) is an enzyme replacement therapy (ERT) indicated for:

- the long-term treatment of patients with late-onset Pompe disease (acid α -glucosidase deficiency).

1.1 Pediatrics

Pediatrics (>6 months of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Nexviazyme in pediatric late-onset Pompe disease (LOPD) patients has been established; therefore, Health Canada has authorized an indication for pediatric use in these patients (see 14 CLINICAL TRIALS). Nexviazyme is not indicated in infantile onset Pompe disease (IOPD) patients; a study with IOPD patients (n=22) is ongoing.

1.2 Geriatrics

Geriatrics (>65 years of age): Limited evidence from clinical studies does not suggest that use in the geriatric population is associated with differences in efficacy or safety.

2 CONTRAINDICATIONS

Life-threatening hypersensitivity to the active substance or to any of the excipients when re-challenge was unsuccessful (see WARNINGS AND PRECAUTIONS, Immune, Hypersensitivity reactions including anaphylaxis). For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Hypersensitivity Reactions Including Anaphylaxis

- Patients treated with NEXVIAZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during NEXVIAZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, NEXVIAZYME should be discontinued immediately and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, a desensitization procedure to NEXVIAZYME may be considered (see 7 WARNINGS AND PRECAUTIONS).

Infusion-Associated Reactions (IARs)

- Patients treated with NEXVIAZYME have experienced severe IARs. If severe IARs occur, consider immediate discontinuation of NEXVIAZYME, initiation of appropriate medical treatment, and the benefits and risks of readministering NEXVIAZYME following severe IARs. Patients with an acute underlying illness at the time of NEXVIAZYME infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs (see 7 WARNINGS AND PRECAUTIONS).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- Vials are single-use only. Any unused product should be discarded.

4.2 Recommended Dose and Dosage Adjustment

Patients with late-onset Pompe disease (LOPD)

The recommended dose of Nexviazyme is 20 mg/kg of body weight administered every other week (qow).

Pediatric patients (>6 months of age)

Based on population-PK modeling, no dose adjustment is required in pediatric LOPD patients (see Section 7 WARNINGS AND PRECAUTIONS, Pediatrics).

Geriatric patients (>65 years of age)

Clinical studies with Nexviazyme included 11 patients aged 65-75 years and 2 patients over the age of 75 years. There is no recommended dose adjustment for patients over the age of 65 (see 14 CLINICAL TRIALS).

Hepatic impairment

The safety and efficacy of Nexviazyme have not been studied in patients with hepatic impairment.

Renal impairment

Based on available data, including population-PK modeling, no dose adjustment is required in patients with mild renal impairment. Nexviazyme has not been studied in patients with moderate or severe renal impairment (see 10 CLINICAL PHARMACOLOGY, Pharmacokinetics).

4.3 Reconstitution

Table 1 - Reconstitution

Vial Size	Volume of Sterile Water for Injection (WFI) to be Added to Vial	Approximate Available Volume	Nominal Concentration per mL
20 mL	10 mL	10.0 mL	10 mg/mL

Following reconstitution, each vial contains 10.3 mL reconstituted solution and a total extractable volume of 10.0 mL at 10 mg/mL of Nexviazyme. Each vial contains an overfill to compensate for liquid loss during preparation. This overfill ensures that, after dilution with the entire content, there is solution containing 10 mg/mL Nexviazyme.

4.4 Administration

Nexviazyme is intended for long-term, chronic use under the guidance and supervision of a health care professional who is knowledgeable in the treatment of Pompe disease. Nexviazyme should be reconstituted, diluted and administered by a health care professional in a hospital or in an appropriate setting of outpatient care.

Nexviazyme is for intravenous (IV) infusion only.

Intravenous (IV) infusion

Infusion should be administered incrementally as determined by patient response and comfort over approximately 4 hours for patients with LOPD. For patients with LOPD, it is recommended that the infusion begins at an initial rate of 1 mg/kg/hour and be gradually increased by 2 mg/kg/hour every 30 minutes if there are no signs of infusion associated reactions (IARs) until a maximum rate of 7 mg/kg/hour is reached. Vital signs should be obtained at each step, before increasing the infusion rate. Patients may be pretreated with antihistamines, antipyretics and/or corticosteroids to prevent or reduce allergic reactions.

In the event of anaphylaxis or severe hypersensitivity reaction or severe infusion associated reactions (IARs), immediately discontinue administration of Nexviazyme and initiate appropriate medical treatment. In the event of mild to moderate hypersensitivity reactions or IARs, the infusion rate may be slowed or temporarily stopped and/or appropriate medical treatment initiated (see 7 WARNINGS AND PRECAUTIONS, Immune, Hypersensitivity reactions including anaphylaxis and Infusion Associated Reactions).

Symptoms may persist despite temporarily stopping the infusion; therefore, the treating physician should wait at least 30 minutes for symptoms of the reactions to resolve before deciding to stop the infusion for the remainder of the day. If symptoms subside, resume infusion rate for 30 minutes at half the rate, or less, of the rate at which the reactions occurred, followed by an increase in infusion rate by 50% for 15 to 30 minutes. If symptoms do not recur, increase the infusion rate to the rate at which the reactions occurred and consider continuing to increase the rate in a stepwise manner until the maximum rate is achieved.

4.7 Instructions for Preparation and Use

Use aseptic technique during preparation.

1. Determine the number of vials to be reconstituted based on the individual patient's weight and the recommended dose of 20 mg/kg.
 - Patient weight (kg) x dose (mg/kg) = patient dose (in mg).
 - Patient dose (in mg) divided by 100 mg/vial = number of vials to reconstitute. If the number of vials includes a fraction, round up to the next whole number.

Example: Patient weight (16 kg) x dose (20 mg/kg) = patient dose (320 mg).
320 mg divided by 100 mg/vial = 3.2 vials; therefore, 4 vials should be reconstituted.

2. Remove the required number of vials needed for the infusion from the refrigerator and set aside for approximately 30 minutes to allow them to reach room temperature.
3. Reconstitute each vial by slowly injecting 10 mL of Sterile Water for Injection (WFI) to each vial. Each vial will yield 100 mg per 10 mL (10 mg/mL). Avoid forceful impact of the water for injection on the powder and avoid foaming. This is done by slow drop-wise addition of the WFI down the inside of the vial and not directly onto the lyophilized cake. Tilt and roll each vial gently. DO NOT invert, swirl, or shake. Avoid any air introduction into the infusion bag during the dilution of the product.

4. Perform an immediate visual inspection on the reconstituted vials for particulate matter and discoloration. If upon immediate inspection particles are observed or if the solution is discolored, DO NOT USE. Allow the solution to become dissolved.
5. The reconstituted solution should be diluted in 5% dextrose in water to a final concentration of 0.5 to 4 mg/mL. See **Error! Reference source not found.** for the recommended total infusion volume based on the patient weight.
6. Slowly withdraw the volume of reconstituted solution from each vial (calculated according to the patient's weight).
7. Add the reconstituted solution slowly and directly into the 5% dextrose solution. Avoid foaming or agitation of the infusion bag. Avoid air introduction into the infusion bag.
8. Gently invert or massage the infusion bag to mix. DO NOT shake.
9. It is recommended to use an in-line low protein binding 0.2 µm filter to administer Nexviazyme. After the infusion is complete, flush with dextrose 5% in water bag.
10. Do not infuse Nexviazyme in the same intravenous line with other products.

Table 2 - Projected intravenous infusion volumes for Nexviazyme administration by patient weight at 20 mg/kg Dose

Patient Weight Range (kg)	Total Infusion Volume for 20 mg/kg (mL)
1.25 to 10	50
10.1 to 20	100
20.1 to 30	150
30.1 to 35	200
35.1 to 50	250
50.1 to 60	300
60.1 to 100	500
100.1 to 120	600
120.1 to 140	700
140.1 to 160	800
160.1 to 180	900
180.1 to 200	1000

5 OVERDOSAGE

There have been no reports of overdose with Nexviazyme. In a clinical study, pediatric patients received doses up to 40 mg/kg of body weight every other week.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

To help ensure the traceability of biologic products, including biosimilars, health professionals should recognize the importance of recording both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 3– Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
intravenous infusion	lyophilized powder 100 mg/vial	Glycine, L-Histidine, L-Histidine HCl monohydrate, mannitol, polysorbate 80

Nexviazyme is supplied in type I colorless clear glass vial closed with a siliconized elastomeric stopper. The stoppered vials are crimped with an aluminum seal with a Flip-Off® button.

Each pack contains 1 vial.

Description

Avalglucosidase alfa is a recombinant human acid α -glucosidase (GAA) with synthetic bis-mannose-6-phosphate (bis-M6P) moieties conjugated to its oxidized sialic acid residues.

7 WARNINGS AND PRECAUTIONS

Cardiovascular

Risk of Acute cardiorespiratory failure

Caution should be exercised when administering Nexviazyme to patients susceptible to fluid volume overload or patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function for whom fluid restriction is indicated. These patients may be at risk of serious exacerbation of their cardiac or respiratory status during infusion. Appropriate medical support and monitoring measures should be readily available during Nexviazyme infusion, and some patients may require prolonged observation times that should be based on the individual needs of the patient.

Cardiac arrhythmia and sudden death during general anesthesia for central venous catheter placement

Caution should be used when administering general anesthesia for the placement of a central venous catheter.

Driving and Operating Machinery

Due caution should be exercised when driving or operating a vehicle or potentially dangerous machinery.

No studies on the effects on the ability to drive and use machines have been performed. Because dizziness has been reported as an IAR, this may affect the ability to drive and use machines on the day of the infusion (see 8 ADVERSE REACTIONS, Clinical Trial Adverse Reactions).

Immune

Hypersensitivity reactions including anaphylaxis

Hypersensitivity reactions, including anaphylaxis, have been reported in Nexviazyme-treated patients. In clinical studies 60 (43.5%) patients experienced hypersensitivity reactions including 6 patients who reported severe hypersensitivity reactions and 2 patients who experienced anaphylaxis. Some of the hypersensitivity reactions were IgE mediated. Anaphylaxis symptoms included respiratory distress, chest pressure, generalized flushing, cough, dizziness, nausea, redness on palms, swollen lower lip, decreased breath sounds, redness on feet, swollen tongue, itchy palms and feet, and oxygen desaturation. Symptoms of severe hypersensitivity reactions included respiratory failure, respiratory distress and rash.

Appropriate medical support measures, including cardiopulmonary resuscitation equipment especially for patients with cardiac hypertrophy and patients with significantly compromised respiratory function, should be readily available when Nexviazyme is administered.

If severe hypersensitivity or anaphylaxis occur, Nexviazyme should be discontinued immediately, and appropriate medical treatment should be initiated. The risks and benefits of re-administering Nexviazyme following anaphylaxis or severe hypersensitivity reaction should be considered. Some patients have been re-challenged using slower infusion rates at a dose lower than the recommended dose. In patients with severe hypersensitivity, desensitization procedure to Nexviazyme may be considered. If the decision is made to re-administer the product, extreme caution should be exercised, with appropriate resuscitation measures available. Once a patient tolerates the infusion, the dose may be increased to reach the approved dose.

If mild or moderate hypersensitivity reactions occur, the infusion rate may be slowed or temporarily stopped.

Infusion Associated Reactions

In clinical studies, IARs were reported to occur at any time during and/or within a few hours after the infusion of Nexviazyme and were more likely with higher infusion rates. IARs were reported in approximately 30.4% of patients treated with Nexviazyme in clinical studies. The majority of IARs were assessed as mild to moderate and included symptoms such as chills, cough, diarrhea, erythema, fatigue, headache, influenza like illness, nausea, ocular hyperemia, pain in extremity, pruritus, rash, rash erythematous, tachycardia, urticaria, vomiting, chest discomfort, dizziness, hyperhidrosis, lip swelling, oxygen saturation decreased, pain, palmar erythema, swollen tongue and tremor. In clinical studies, 3 (2.2%) patients reported severe IARs including symptoms of chest discomfort, nausea and increased blood pressure.

Patients with an acute underlying illness at the time of Nexviazyme infusion appear to be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs. Antihistamines, antipyretics, and/or corticosteroids can be given to prevent or reduce IARs. However, IARs may still occur in patients after receiving pre-treatment.

If severe IARs occur, immediate discontinuation of the administration of Nexviazyme should be considered and appropriate medical treatment should be initiated. The benefits and risks of re-administering Nexviazyme following severe IARs should be considered. Some patients have been re-challenged using slower infusion rates at a dose lower than the recommended dose. Once a patient tolerates the infusion, the dose may be increased to reach the approved dose. If a mild or moderate

IARs occur regardless of pre-treatment, decreasing the infusion rate or temporarily stopping the infusion may ameliorate the symptoms.

Guide for healthcare professionals (HCPs) for immunosurveillance service

A “Guide for healthcare professionals (HCPs) for immunosurveillance service” is available to help manage the following safety concerns for Nexviazyme:

- Infusion associated reactions including hypersensitivity and anaphylactic reactions, with or without development of IgG and IgE antibodies
- Immunogenicity leading to loss of response (High Sustained IgG Antibody Titers and/or neutralizing antibodies)

The guide also provides information about the immunosurveillance service made available by Sanofi in Canada. The guide is available upon request by phone (1-800-589-6215) or accessed at (www.sanofi.ca).

Immunogenicity

Treatment emergent anti-drug antibodies (ADA) were reported in both treatment naïve (95%) and treatment experienced patients (49%) (see 8 ADVERSE REACTIONS, Clinical Trial Adverse Reactions, Immunogenicity).

IARs and hypersensitivity reactions may occur independent of the development of ADA. The majority of IARs and hypersensitivity reactions were mild or moderate and were managed with standard clinical practices. In treatment-naïve patients, a trend for increases in the incidence of IARs was observed with increasing ADA titers, with the highest incidence of IARs (61.5%) reported in the high ADA peak titer range $\geq 12,800$, compared with an incidence of 24.1% in patients with intermediate ADA titer 1,600-6,400, an incidence of 7.1% in those with low ADA titer 100-800 and an incidence of 33.3% in those who were ADA negative. In clinical studies, the development of ADA did not have an apparent impact on efficacy.

ADA testing may be considered if patients do not respond to therapy. Adverse-event-driven immunologic testing, including IgG and IgE ADA, may be considered for patients who have risk for allergic reaction or previous anaphylactic reaction to alglucosidase alfa.

Monitoring and Laboratory Tests

There are no marketed tests for antibodies against Nexviazyme. It is recommended that patients be monitored for IgG antibody formation periodically.

Patients who experience reactions suggestive of anaphylactic or allergic reactions may also be tested for IgE antibodies to avalglucosidase alfa and other mediators of anaphylaxis. If testing is warranted, contact your local Sanofi Genzyme representative or Sanofi Genzyme Canada at 1-800-589-6215.

Patients should be informed that a registry for patients with Pompe disease has been established in order to better understand the variability and progression of Pompe disease and to continue to monitor and evaluate treatments. Patients should be encouraged to participate and advised that their participation may involve long-term follow-up. Information regarding the registry program may be found at www.registrynxt.com or by calling 1-800-745-4447, extension 15500.

7.1 Special Populations

7.1.1 Pregnant Women

There are no available data on the use of Nexviazyme in pregnant women. An embryo-fetal toxicity study performed in pregnant mice administered avalglucosidase alfa intravenously resulted in maternal toxicity related to an immunologic response (including an anaphylactoid response) and increased post-implantation loss (see 16 NON-CLINICAL TOXICOLOGY).

Nexviazyme is not recommended in pregnancy. Available data from case reports of Nexviazyme use in pregnant women are insufficient to evaluate for a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. All women of childbearing potential prescribed Nexviazyme should have a discussion around contraception with their Health Care Professional and adequate contraception should be advised. Women exposed during pregnancy should be encouraged to enroll in the Pompe registry. If a patient wishes to become pregnant, or became pregnant, the decision to discontinue Nexviazyme treatment should be discussed with their Health Care Professional (see 10 CLINICAL PHARMACOLOGY).

7.1.2 Breast-feeding

Nexviazyme is not recommended while breast-feeding. There are no available data on the presence of Nexviazyme in human milk or the effects of Nexviazyme on milk production or the breastfed infant. A risk to the newborn/infant cannot be excluded (see 16 NON-CLINICAL TOXICOLOGY).

7.1.3 Pediatrics

The safety of Nexviazyme in pediatric patients older than 6 months with Pompe disease is limited. There are no data available in patients 6 months of age and younger. The safety of Nexviazyme was assessed in 1 pediatric patient with LOPD (16 years of age) in the pivotal clinical trial, and 22 pediatric patients with IOPD (1 to 12 years of age) in an ongoing clinical trial (see 14 CLINICAL TRIALS and 8 ADVERSE REACTIONS, Clinical Trial Adverse Reactions).

7.1.4 Geriatrics

Of the 95 patients with LOPD exposed to Nexviazyme in the pivotal clinical trial, 11.6% (n=11) were aged between 65-75 years of age and 2.1% (n=2) patients were over 75 years of age. Differences in efficacy and safety between these patients and younger patients have not been determined due to limited clinical trial experience in geriatric patients.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Serious adverse reactions reported in patients treated with Nexviazyme were headache, dyspnea, respiratory distress, nausea, skin discoloration, chills, chest discomfort, pyrexia, blood pressure increased, body temperature increased, heart rate increase, and oxygen saturation decreased. A total of 2 patients receiving Nexviazyme in clinical studies permanently discontinued treatment, of these 1 patient discontinued the treatment because of serious adverse event. The most frequently reported adverse drug reactions (ADRs) (>5%) were headache, nausea, pruritus, rash, urticaria, fatigue and chills.

IARs were reported in 30.4% of patients. IARs reported in more than one patient included chills, cough, diarrhea, erythema, fatigue, headache, influenza-like illness, nausea, ocular hyperemia, pain in extremity, pruritus, rash, rash erythematous, tachycardia, urticaria, vomiting, chest discomfort, dizziness, hyperhidrosis, lip swelling, oxygen saturation decreased, pain, palmar erythema, swollen tongue and tremor. The majority of IARs were assessed as mild to moderate (see 7 WARNINGS AND PRECAUTIONS, Immune, Infusion Associated Reactions).

8.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Adverse Reactions from Clinical Trials in the Pompe Disease Population

The pooled safety analysis from three pivotal and supportive studies in LOPD (118 adults and 1 pediatric patient) and an ongoing study in IOPD (22 pediatric patients).

ADRs reported in at least 3 patients ($\geq 2\%$) treated with Nexviazyme in the pooled analysis of clinical studies are listed in Table 4. Serious adverse events were consistent across adult and pediatric populations.

Infusion associated reactions (IARs) were reported in 42 (30.4%) of Nexviazyme-treated subjects. IARs reported in more than 1 subject included chills, cough, diarrhea, erythema, fatigue, headache, influenza-like illness, nausea, ocular hyperemia, pain in extremity, pruritus, rash, rash erythematous, tachycardia, urticaria, vomiting, chest discomfort, dizziness, hyperhidrosis, lip swelling, oxygen saturation decreased, pain, palmar erythema, swollen tongue, abdominal pain upper, burning sensation, eyelid edema, feeling cold, flushing, respiratory distress, throat irritation, and tremor (see 7 WARNINGS AND PRECAUTIONS).

Table 4 - Adverse reactions occurring in at least 3 patients ($\geq 2\%$) treated with Nexviazyme in pooled analysis of clinical studies

	Nexviazyme patients (N = 138) n (%)
Nervous system disorders	
Headache	10 (7.2)
Dizziness	4 (2.9)
Respiratory, thoracic and mediastinal disorders	
Cough	3 (2.2)
Dyspnea	3 (2.2)
Gastrointestinal disorders	
Nausea	8 (5.8)
Diarrhea	3 (2.2)

Table 4 - Adverse reactions occurring in at least 3 patients (≥ 2%) treated with Nexviazyme in pooled analysis of clinical studies

	Nexviazyme patients (N = 138) n (%)
Skin and subcutaneous tissue disorders	
Pruritus	13 (9.4)
Rash	11 (8.0)
Urticaria	9 (6.5)
Erythema	4 (2.9)
Musculoskeletal and connective tissue disorders	
Muscle spasms	4 (2.9)
Myalgia	4 (2.9)
General disorders and administration site conditions	
Fatigue	9 (6.5)
Chills	7 (5.1)
Chest discomfort	3 (2.2)
Pain	3 (2.2)

Adverse Reactions from Clinical Trials in Late-Onset Pompe Disease (LOPD)

In a comparative study, EFC14028, of 100 LOPD patients aged 16 to 78 naïve to enzyme replacement therapy 51 were treated with 20 mg/kg of Nexviazyme. Serious adverse reactions were reported in 2% of patients treated with Nexviazyme; none of the patients permanently discontinued the treatment. The most frequently reported ADRs (>5%) were headache, nausea, pruritus, urticaria, and fatigue.

Pediatrics

The safety profile of Nexviazyme in pediatric patients 1 to 12 years old with Pompe disease was consistent with the safety profile of Nexviazyme in older pediatric and adult patients. The safety and effectiveness of Nexviazyme have not been established in pediatric patients younger than 1 year of age.

Immunogenicity

Treatment emergent anti-drug antibodies (ADAs) were reported in both treatment naïve and treatment experienced patients (see 7 WARNINGS AND PRECAUTIONS, Immune). IARs and hypersensitivity reactions may occur independent of the development of ADAs.

Hypersensitivity reactions including anaphylaxis

In clinical studies 60 (43.5%) patients experienced hypersensitivity reactions including 6 patients who reported severe hypersensitivity reactions and 2 patients who experienced anaphylaxis (see 7 WARNINGS AND PRECAUTIONS, Immune). Some of the hypersensitivity reactions were IgE mediated. Anaphylaxis symptoms included respiratory distress, chest pressure, generalized flushing, cough, dizziness, nausea, redness on palms, swollen lower lip, decreased breath sounds, redness on feet, swollen tongue, itchy palms and feet, and oxygen desaturation. Symptoms of severe hypersensitivity reactions included respiratory failure, respiratory distress and rash.

Infusion Associated Reactions

IARs were reported in approximately 42 (30.4 %) of patients treated with Nexviazyme in clinical studies (see 7 WARNINGS AND PRECAUTIONS, Immune). In clinical studies, 3 (2.2%) patients reported severe

IARs including symptoms of chest discomfort, nausea and increased blood pressure (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX).

There were no reports of severe IARs in patients treated with Nexviazyme. IARs were reported in 25.5% of the patients treated with Nexviazyme. All the IARs reported in more than 1 patient were mild to moderate and included headache, chills, dizziness, erythema, diarrhea, nausea, pruritus, rash, and urticaria.

9 DRUG INTERACTIONS

9.4 Drug-Drug Interactions

No drug-drug interaction studies have been conducted with Nexviazyme. Interactions with other drugs have not been established.

9.5 Drug-Food Interactions

No drug-food interaction studies have been conducted with Nexviazyme. Interactions with food has not been established.

9.6 Drug-Herb Interactions

No drug-herb interaction studies have been conducted with Nexviazyme. Interactions with herbal products have not been established

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Pompe disease (also known as glycogen storage disease type II, acid maltase deficiency, and glycogenosis type II) is a rare metabolic muscle disease inherited in an autosomal recessive manner defined by a deficiency of acid α -glucosidase (GAA), which is necessary for the degradation of lysosomal glycogen. GAA cleaves alpha-1,4 and alpha-1,6 linkages in glycogen under the acidic conditions of the lysosome. Pompe disease results in intra-lysosomal accumulation of glycogen in various tissues, particularly cardiac and skeletal muscles, leading to the development of cardiomyopathy, progressive muscle weakness, and impairment of respiratory function.

Avalglucosidase alfa is a recombinant human acid α -glucosidase (rhGAA) that provides an exogenous source of GAA. Avalglucosidase alfa is a modification of alglucosidase alfa in which approximately 7 hexamannose structures each containing 2 terminal mannose-6-phosphate (bis-M6P) moieties are conjugated to oxidized sialic acid residues on alglucosidase alfa. Avalglucosidase alfa has a 15-fold increase in mannose-6-phosphate (M6P) moieties compared with alglucosidase alfa. Increasing the level of bis-M6P on rhGAA provides a mechanism to drive uptake into the diaphragm and other skeletal muscle via the cation-independent M6P receptor.

10.2 Pharmacodynamics

In fifty-one treatment-naïve LOPD patients aged 16 to 78, the mean percentage (SD) change in urinary hexose tetrasaccharides from baseline for patients treated with Nexviazyme 20 mg/kg every other week was -53.90% (24.03), at week 49.

10.3 Pharmacokinetics

Table 5 - Summary of avalglucosidase alfa Pharmacokinetic Parameters in LOPD patients derived from population modeling

	C_{max} ($\mu\text{g}/\text{mL}$)	t_{max} (h)	$t_{1/2}$ (h)	AUC_{2w} ($\mu\text{g}\cdot\text{h}/\text{mL}$)	CL (L/h)	Distribution volume (L)
20 mg/kg mean	273	4.0	1.55	1220	0.87	3.4

Median reported for t_{max} ; C_{max} = maximum plasma concentration; t_{max} = time to reach the maximum plasma concentration; $t_{1/2}$ = terminal elimination half-life; AUC_{2w} = area under the plasma concentration-time curve over the dosing interval (2 weeks); CL = total plasma clearance

Patients with late-onset Pompe disease (LOPD)

The pharmacokinetics of avalglucosidase alfa was evaluated in a population analysis of 75 LOPD patients aged 16 to 78 years who received 5 to 20 mg/kg of avalglucosidase alfa every other week for up to 5 years.

Absorption: The exposure to avalglucosidase alfa increased in a dose-proportional manner between 5 to 20 mg/kg in LOPD patients. No accumulation was observed following every other week dosing.

In LOPD patients, the population PK model predicted a mean C_{max} and mean AUC_{2w} of 273 $\mu\text{g}/\text{mL}$ and 1220 $\mu\text{g}\cdot\text{h}/\text{mL}$, respectively following 20 mg/kg every other week dosing.

Distribution: In LOPD patients, the typical population PK model predicted central compartment volume of distribution of avalglucosidase alfa was 3.4 L.

Metabolism: The metabolic pathway of avalglucosidase alfa has not been characterized. As a glycoprotein, avalglucosidase alfa is expected to be degraded into small peptides or amino acids via non-saturable catabolic pathways.

Elimination: In LOPD patients, the typical population PK model predicted linear clearance was 0.87 L/h. Following 20 mg/kg every other week dosing, the mean plasma elimination half-life was 1.55 hours.

Special Populations and Conditions

Geriatrics: Population pharmacokinetic analyses in LOPD patients showed that age, did not meaningfully influence the pharmacokinetics of avalglucosidase alfa.

Sex: Population pharmacokinetic analyses in LOPD patients showed that gender did not meaningfully influence the pharmacokinetics of avalglucosidase alfa.

Hepatic Insufficiency: The pharmacokinetics of avalglucosidase alfa have not been studied in patients with hepatic impairment.

Renal Insufficiency: No formal study of the effect of renal impairment on the pharmacokinetics of avalglucosidase alfa was conducted. On the basis of a population pharmacokinetic analysis of data from 75 LOPD patients receiving 20 mg/kg every other week, including 6 patients with mild renal impairment

(glomerular filtration rate: 60 to 89 mL/min; at baseline), no relevant effect of renal impairment on exposure to avalglucosidase alfa was observed.

11 STORAGE, STABILITY AND DISPOSAL

Store in a refrigerator between 2°C to 8°C. Do not use Nexviazyme after the expiration date on the vial.

Shelf-Life (after reconstitution and dilution)

The reconstituted and diluted solution should be administered without delay. The reconstituted product can be stored up to 24 hours when refrigerated at 2°C and 8°C and the diluted product can be stored up to 24 hours when refrigerated at 2°C to 8°C and up to 9 hours (including infusion time) when stored at room temperature (up to 27°C).

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance


Proper name: avalglucosidase alfa

Chemical name: Recombinant human acid α -glucosidase conjugated with synthetic bis-mannose-6-phosphate (bis-M6P).

Molecular formula: $C_{4490}H_{6829}N_{1197}O_{1298}S_{32}$, protein

Total molecular mass including glycan: approximately 124 kDa

Structural formula:



Physicochemical properties: Avalglucosidase alfa concentrate solution for infusion, after reconstitution, is a clear, colorless to pale yellow solution, and essentially free of visible particles.

Product Characteristics

Nexviazyme is a sterile white to pale yellow lyophilized powder. After reconstitution it is a clear, colourless to pale yellow solution.

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Table 6- Summary of patient demographics for clinical trials in late-onset Pompe disease

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex (M/F)
EFC14028 (COMET)	Phase 3, multicenter, multinational, randomized, double-blind, 49-weeks Primary Analysis Period (PAP) study long-term, open label Extension Treatment Period (ETP)	Test: Avalglucosidase alfa: 20 mg/kg qow Reference: Alglucosidase alfa: 20 mg/kg qow Intravenous infusion Duration: PAP: 49 weeks ETP: 5-years long	100	48.1 (16-78)	52/48

Clinical Trials in patients with LOPD

Study EFC14028, was a multinational, multicenter, randomized, double-blinded study comparing the efficacy and safety of Nexviazyme and alglucosidase alfa in 100 treatment-naïve LOPD patients aged 3 years or older at the initiation of treatment. Patients were randomized in a 1:1 ratio based on baseline forced vital capacity (FVC), gender, age, and country to receive 20 mg/kg of Nexviazyme or alglucosidase alfa once every other week for 12 months (49 weeks). The study included an open-label, long-term, follow-up phase of up to 5 years for all patients, in which patients in the alglucosidase alfa arm were switched to treatment with Nexviazyme.

14.2 Study Results

The primary endpoint of study EFC14028 was the change in FVC (% predicted) in the upright position from baseline to 12 months (week 49). The study met its primary objective of demonstrating the non-inferiority of Nexviazyme to alglucosidase alfa based on the pre-specified margin of -1.1%. Results are shown in Table 7.

Table 7 - LS mean change from baseline to week 49 in FVC (% predicted) in upright position

Primary Endpoints	Nexviazyme (n=51)	alglucosidase alfa (n=49)
Forced Vital Capacity (Percent of predicted normal)		
Pre- treatment Baseline		
Mean (SD)	62.5 (14.4)	61.6 (12.4)
Week 49		
Mean (SD)	65.49 (17.42)	61.16 (13.49)

Table 7 - LS mean change from baseline to week 49 in FVC (% predicted) in upright position

Primary Endpoints	Nexviazyme (n=51)	alglucosidase alfa (n=49)
Estimated Change from Baseline to Week 49 (MMRM) LS Mean (SE)	2.89* (0.88)	0.46* (0.93)
Estimated Difference Between Groups in Change from Baseline to Week 49 (MMRM) LS Mean (95% CI) p-value**	2.43* (-0.13,4.99) 0.0074	

MMRM: mixed model repeated measure.

*On the basis of MMRM model, the model includes baseline FVC (% predicted, as continuous), sex, age (in years at baseline), treatment group, visit, interaction term between treatment group and visit as fixed effects.

** Non-inferiority margin of -1.1%.

The key secondary endpoint of study EFC14028 was change in total distance walked in 6 minutes (6-Minute Walk Test, 6MWT) from baseline to 12 months (week 49). At week 49, the LS mean change from baseline (SE) in 6MWT for patients treated with Nexviazyme and alglucosidase alfa was 32.21 m (9.93) and 2.19 m (10.40) respectively. LS mean change from baseline to week 49 for additional secondary endpoints (Maximum Inspiratory Pressure, Maximum Expiratory Pressure, Hand-held dynamometry, Quick Motor function Test, 12-item short-form health survey) showed numerically greater benefit of Nexviazyme over alglucosidase alfa.

14.4 Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Nexviazyme in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

The incidence of ADA response to avalglucosidase alfa in Nexviazyme-treated patients with Pompe disease is shown in **Error! Reference source not found..** The median time to seroconversion was 8.3 weeks.

Table 8 – Incidence of ADA response in patients with LOPD

	Nexviazyme		
	Treatment-naïve patients Avalglucosidase alfa ADA (N=61) ^d	Treatment experienced patients Avalglucosidase alfa ADA (N=61) ^e	
	Adults 20 mg/kg every other week (N=61) N (%)	Adults 20 mg/kg every other week (N=55) N (%)	Pediatric 20 mg/kg every other week (N=6) N (%)
ADA at baseline	2 (3.3)	40 (72.7)	1 (16.7)
Treatment emergent ADA ^a	58 (95.1)	27 (49.1)	1(16.6)
Treatment-induced ADA ^c	56 (94.9)	9 (60.0)	1 (16.6)

Table 8 – Incidence of ADA response in patients with LOPD

	Nexviazyme		
	Treatment-naïve patients Avalglucosidase alfa ADA (N=61) ^d	Treatment experienced patients Avalglucosidase alfa ADA (N=61) ^e	
	Adults 20 mg/kg every other week (N=61) N (%)	Adults 20 mg/kg every other week (N=55) N (%)	Pediatric 20 mg/kg every other week (N=6) N (%)
Treatment-boosted ADA ^b	2 (100)	18 (45.0)	0
Neutralizing antibody			
Both NAb types	13 (21.1)	2 (3.6)	0
Inhibition enzyme activity, only	4 (6.6)	8 (14.5)	0
Inhibition of enzyme uptake, only	10 (16.4)	8 (14.5)	0

^a Treatment emergent = Treatment induced + Treatment boosted.

^b Treatment -boosted ADA incidence defined as 100x (Treatment boosted ADA positive patients)/(number of evaluable patients with ADA positive at baseline).

^c Treatment induced ADA incidence is defined as 100 x (Treatment induced ADA positive patients)/(number of evaluable patients with ADA negative at baseline).

^d Treatment naïve: only treated with avalglucosidase alfa

^e Treatment experienced: previously treated with alglucosidase alfa. Treatment-experienced patients received alglucosidase alfa treatment within a range of 0.9-9.9 years for adult patients and 0.5-11.7 years for pediatric patients before receiving NEXVIAZYME.

In treatment-naïve adult patients, the occurrence of IARs was observed in both ADA-positive and ADA-negative patients. Increase in the incidence of IARs and hypersensitivity were observed with higher IgG ADA titers. In enzyme replacement therapy (ERT) experienced adult patients, the occurrences of IARs and hypersensitivity were higher in patients who developed treatment emergent ADA compared to patients who were ADA negative. One (1) treatment naïve patient and 1 treatment experienced patient developed anaphylaxis. The occurrences of IARs were similar between pediatric patients with ADA positive and negative status. There were no pediatric patients who developed anaphylactic reactions (see 7 WARNINGS AND PRECAUTIONS, Immune, Immunogenicity).

In clinical study EFC14028, 2 patients reported High Sustained Antibody Titers (HSAT) to Nexviazyme but this was not associated with a loss of efficacy. ADA cross reactivity studies showed that the majority of patients generate antibodies that are cross-reactive to alglucosidase alfa. At week 49, antibodies specific to Nexviazyme were detected in 3 (5.9%) patients. ADA did not impact measures of efficacy while limited impacts on PK and PD were observed primarily with high titer patients.

In the study EFC14028, 49 of 51 (96.1%) LOPD patients receiving Nexviazyme developed treatment-emergent ADA. As only 2 patients were ADA negative, the ADA impact on PK was assessed by categorizing the ADA-positive patients into 3 peak titer groups: ≤800, 1,600-6,400, and ≥12,800. The development of ADA did not have an apparent impact on clinical efficacy. The median time to seroconversion was 8 weeks. No clear trend of ADA impact on PK was observed. A trend toward decreased PD response as measured by percent change of urinary glucose tetrasaccharides from baseline was observed in patients with ADA peak titer ≥12,800. Five patients had ≥50% change in the

AUC at week 49 from baseline but no obvious pattern in titers. Inter-subject comparison of the AUC at Day 1 or 2 and week 49 supported the overall analysis of percent change in the AUC and ADA positivity categorized by ADA titers. In vitro evaluation of neutralizing antibodies that inhibited enzyme activity or inhibited cellular uptake demonstrated no clear relationship of assay positivity with AUC.

16 NON-CLINICAL TOXICOLOGY

General Toxicology

In a 26-week repeat-dose toxicity study, avalglucosidase alfa was administered to monkeys at a dose of 0 (vehicle), 50, or 200 mg/kg IV (intravenously) once every 2 weeks. No adverse effects were observed. The NOAEL was 200 mg/kg IV every other week (23-fold higher than the human exposure at the maximum recommended human dose [MRHD] based on AUC). The results for some animals in the dosing groups were confounded by technical error associated with the surgical procedure.

Carcinogenicity

Carcinogenicity studies with avalglucosidase alfa were not conducted.

Genotoxicity

Genotoxicity studies with avalglucosidase alfa were not conducted.

Reproductive and Developmental Toxicity

Some reproductive toxicity studies in mice included pre-treatment with diphenylhydramine to prevent or minimize hypersensitivity reactions. Rabbits were not pretreated with DPH because hypersensitivity reactions were not observed. Avalglucosidase alfa does not cross the placenta in mice, therefore, there is no fetal exposure to avalglucosidase alfa in the mouse developmental and reproductive toxicity studies. Exposure to avalglucosidase alfa from maternal milk was not assessed.

Fertility

The effects of avalglucosidase alfa on mating performance, fertility, and early embryonic development were evaluated in a fertility study in male and female mice administered 0 (vehicle), 10, 20, or 50 mg/kg IV every 2 days (3.5-, 7-, or 17.5-fold higher than the MRHD on a mg/kg basis, respectively). Male mice were dosed before to cohabitation (10 weeks) and female mice were dosed through conception to Gestational Day (GD) 7 (2 weeks). Death related to an immunologic response (including an anaphylactoid response) occurred at all doses. There were no adverse effects on male or female fertility. A NOAEL could not be determined based on the hypersensitivity reaction deaths that occurred at the lowest dose.

Embryo-Fetal Development

Pregnant mice were administered avalglucosidase alfa at a dose of 0 (vehicle) 10, 20 or 50 mg/kg IV once daily on GD 6 through 15. Caesarean sections were performed on GD18. Placental transfer studies determined that avalglucosidase alfa is not transported from the maternal to the fetal circulation. Maternal death at 50 mg/kg/day was considered related to an immunologic response (including an anaphylactoid response). Increased post implantation loss and mean number of late resorptions were observed at this dose that may be related to the immunologic response in the mothers. The maternal, and the developmental NOAEL were 20 mg/kg/day IV (4.8-fold higher than the human exposure at the MRHD based on AUC).

Pregnant rabbits were administered avalglucosidase alfa at doses of 0 (vehicle), 30, 60, and 100 mg/kg/day IV once per day during organogenesis (GD6 to 19). Caesarian sections were performed on GD 29. Effects on maternal body weight and food consumption were observed. No adverse embryo-fetal effects occurred. The maternal NOAEL was 30 mg/kg/day IV (14.5-fold higher than the human exposure at 20 mg/kg based on AUC) and the developmental NOAEL was 100 mg/kg/day IV (91-fold higher than the human exposure at the MRHD based on AUC).

Pre- and Postnatal Development

Pregnant mice were administered avalglucosidase alfa at doses of 0 (vehicle), 10, 20 or 50 mg/kg IV every 2 days from implantation and continuing through gestation and lactation, through weaning (GD6 through postnatal [PND] day 20). There was no effect on F1 development, sexual maturation, or neurobehavioral parameters. The maternal NOAEL and the NOAEL for reproduction in the dams and for viability and growth in the offspring were 50 mg/kg/dose IV (17.5-fold higher than the MRHD on a mg/kg basis).

Juvenile Toxicity

In a juvenile toxicity study, mice were administered avalglucosidase alfa (at 0 [vehicle], 20, 50, or 100 mg/kg IV once every 2 weeks in females and 0, 25, 50, or 100 mg/kg IV once every 2 weeks in males; (below 1-, equal to 1,- or 2-fold, and 4- to 7-fold higher than the human exposure at the MRHD based on AUC, respectively) for approximately 9 weeks from PND21. Death related to an immunologic response (including an anaphylactoid response) was observed at all doses without dose-response. Increased white blood cell parameters were observed in surviving males, consistent with an immunologic (anaphylactoid) response. There were no effects on developmental neurobehavioral functional parameters (motor activity, learning and memory, and auditory [startle] reflex), sexual maturation, or fertility. A NOAEL could not be determined based on the hypersensitivity reaction deaths that occurred at the lowest dose.

Drug Abuse Liability Potential

Drug abuse liability assessment studies were not performed.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **NEXVIAZYME™**

avalglucosidase alfa for injection, Lyophilized Powder

Read this carefully before you start taking **Nexviazyme** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Nexviazyme**.

Serious Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis**
If you are treated with Nexviazyme you may experience a life-threatening hypersensitivity reaction, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Nexviazyme administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, Nexviazyme should be discontinued immediately and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, a desensitization procedure to Nexviazyme may be considered.
- **Infusion-Associated Reactions (IARs)**
If you are treated with Nexviazyme you may experience an infusion-associated reaction. An infusion-associated reaction is defined as any related side effect occurring during the infusion or during the 2 hours following infusion. Life-threatening allergic reactions, including anaphylactic shock, have been observed in patients during Nexviazyme infusion. Because of the potential for severe infusion reactions, immediate discontinuation of Nexviazyme should be considered, initiation of appropriate medical treatment, should be readily available when Nexviazyme is administered, the benefit risks and risks of readministering Nexviazyme following severe infusion reactions.

Individuals with an acute underlying illness [e.g. fever, pneumonia or sepsis (severe infection), wheezing/difficulty in breathing, heart failure] at the time of Nexviazyme infusion appear to be at greater risk for infusion reactions. Careful consideration should be given to your clinical status prior to administration of Nexviazyme.

What is Nexviazyme used for?

- Nexviazyme is a medicine that is used to treat adults, children and adolescents who have a confirmed diagnosis of late-onset Pompe disease.

How does Nexviazyme work?

- People with Pompe disease have low levels of an enzyme called acid alpha-glucosidase (GAA)
- This enzyme helps the body control levels of glycogen
 - Glycogen is a type of sugar that provides the body with energy
- In Pompe disease the levels of glycogen can get too high.
 - Too much sugar builds up and damages your muscles and organs

- Pompe disease causes muscle weakness and trouble breathing:
 - It mostly affects the liver, heart, and muscles
- People with Pompe disease are not able to make enough of this enzyme
- Nexviazyme contains an artificial enzyme called avalglucosidase alfa;
 - it can replace the natural enzyme which is lacking in Pompe disease

What are the ingredients in Nexviazyme?

Medicinal ingredient: avalglucosidase alfa

Non-medicinal ingredients: Glycine, L-Histidine, L-Histidine HCl monohydrate, mannitol, polysorbate 80

Nexviazyme comes in the following dosage forms:

lyophilized powder, 100 mg/vial (10 mg/mL)

Do not use Nexviazyme if:

- If you have experienced life-threatening allergic (hypersensitive) reactions to avalglucosidase alfa or its ingredients or components of the container and re-administration of the medicine was not successful.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Nexviazyme. Talk about any health conditions or problems you may have, including if you:

- Have had a severe hypersensitivity or anaphylactic reaction to administration of Nexviazyme.
- Have had experience allergic reactions (see “What are the possible side effects from using Nexviazyme” section) or infusion-associated reactions (IARs) while you were given the medicine or during the hours following the infusion
- Are at increased risk of lung infections due to the progressive effects of the disease on the lung muscles
- Are pregnant, think you may be pregnant or plan to become pregnant or are breast feeding
- Are driving or using any tools or machines shortly after infusion of Nexviazyme, since you may experience dizziness.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

How to take Nexviazyme:

Nexviazyme will be given to you under the supervision of a healthcare professional who is experienced in the treatment of Pompe disease.

The dose you receive is based on your body weight and will be given to you once every other week.

Nexviazyme is given through a drip into a vein (by intravenous infusion). It is supplied as a powder which will be mixed with sterile water before it is given.

Usual dose:

Late-onset Pompe disease (LOPD)

The recommended dosage of Nexviazyme is 20 mg per kg of body weight once every other week as an intravenous infusion.

Overdose:

There is no experience with overdose of Nexviazyme.

If you think you have taken too much Nexviazyme, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you have missed an infusion, please contact your doctor. If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

What are possible using side effects from Nexviazyme?

These are not all the possible side effects you may feel when taking Nexviazyme. If you experience any side effects not listed here, contact your healthcare professional.

Side effects were mainly seen while patients were being given the medicine or shortly after (“infusion associated reactions (IARs)”). Allergic reactions may include symptoms such as difficulty breathing, chest pressure, generalized flushing, cough, dizziness, nausea, redness on palms, swollen lower lip and tongue, decreased breath sounds, redness on feet, itchy palms and feet, low level of oxygen in the blood, and rash. IARs may include symptoms such as chest discomfort, increased blood pressure, chills, cough, diarrhea, redness of skin, fatigue, headache, influenza-like illness, nausea, redness of eye, pain in extremity, itchy skin, rash, red rash, increase in heart rate, hives or vomiting. The majority of the IARs were mild to moderate. If you experience any reaction similar to this, tell your doctor immediately. You may need to be given pre-treatment medicines to prevent an allergic reaction (e.g., antihistamines and/or corticosteroids) or to reduce fever (antipyretics).

If you experience swelling of your lower limbs or generalized swelling, please inform your doctor.

Common: may affect up to 1 in 10 people

- Headache
- Dizziness
- Cough
- Difficulty breathing
- Nausea
- Diarrhea
- Vomiting
- Itchy skin
- Hives
- Rash
- Redness of skin
- Muscle spasms
- Muscle aches
- Fatigue
- Chills
- Chest discomfort
- Pain

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Unopened vials – before reconstitution

Store in refrigerator between 2°C - 8°C. Do not use Nexviazyme after the expiration date on the vial. The expiry date refers to the last day of the month.

After reconstitution and dilution

After dilution, an immediate use is recommended. The reconstituted product can be stored up to 24 hours when refrigerated at 2°C -8°C and diluted product can be stored up to 24 hours when refrigerated at 2°C -8°C or up to 9 hours (including infusion time) when stored at room temperature up to 27°C.

Keep out of reach and sight of children.

If you want more information about Nexviazyme:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada.html>); the manufacturer's website www.sanofi.ca, or by calling 1-800-265-7927.

Pompe Registry:

Sanofi Genzyme informs all patients with Pompe Disease that a registry has been established in order to better understand the variability and progression of Pompe Disease and to continue to monitor and evaluate the safety and efficacy of **Nexviazyme**. All patients are encouraged to participate and advised that their participation may involve long-term follow-up. Information regarding the registry program may be found at www.registrynxt.com or by calling 1-800-745-4447, extension 15500.

This leaflet was prepared by sanofi-aventis Canada Inc.

Last Revised May 11, 2023